{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:13:03Z","timestamp":1794975183873,"version":"4.9.1"},"reference-count":253,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,23]],"date-time":"2017-04-23T00:00:00Z","timestamp":1492905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","award":["P30CA014599"],"award-info":[{"award-number":["P30CA014599"]}],"id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AT004418"],"award-info":[{"award-number":["AT004418"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DE020140"],"award-info":[{"award-number":["DE020140"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People&apos;s Republic of China","doi-asserted-by":"publisher","award":["2011CB707906"],"award-info":[{"award-number":["2011CB707906"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["OR130096"],"award-info":[{"award-number":["OR130096"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000430"],"award-info":[{"award-number":["UL1 TR000430"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003359","name":"Scoliosis Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes &amp; Diseases"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.gendis.2017.04.001","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T00:00:42Z","timestamp":1493251242000},"page":"43-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":627,"title":["Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine"],"prefix":"10.1016","volume":"4","author":[{"given":"Cody S.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot S.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan M.","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyue","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingye","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Athiviraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Moriatis","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell R.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-Chuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: the first effective in vivo gene delivery vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/1566523013348689","article-title":"Adenoviral vector-mediated gene transfer for human gene therapy","volume":"1","author":"Breyer","year":"2001","journal-title":"Curr Gene Ther"},{"issue":"9","key":"10.1016\/j.gendis.2017.04.001_bib4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1089\/hum.2011.2517","article-title":"Adenovirus: teaching an old dog new tricks","volume":"22","author":"Seymour","year":"2011","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejcb.2011.01.006","article-title":"New insights into stability of recombinant adenovirus vector genomes in mammalian cells","volume":"91","author":"Rauschhuber","year":"2012","journal-title":"Eur J Cell Biol"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7150\/thno.6914","article-title":"Current progress in gene delivery technology based on chemical methods and nano-carriers","volume":"4","author":"Jin","year":"2014","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib7","first-page":"46","article-title":"Non-viral gene delivery methods","volume":"14","author":"Wang","year":"2013","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2230-973X.108958","article-title":"Novel gene delivery systems","volume":"3","author":"Manjila","year":"2013","journal-title":"Int J Pharm Investig"},{"key":"10.1016\/j.gendis.2017.04.001_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/2277-9175.98152","article-title":"Viral and nonviral delivery systems for gene delivery","volume":"1","author":"Nayerossadat","year":"2012","journal-title":"Adv Biomed Res"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib10","first-page":"33","article-title":"Progress in gene therapy: a review","volume":"1","author":"Katare","year":"2010","journal-title":"Int J Toxicol Pharm Res"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib11","first-page":"RA110","article-title":"Vectors and delivery systems in gene therapy","volume":"11","author":"Gardl\u00edk","year":"2005","journal-title":"Med Sci Monit"},{"issue":"21","key":"10.1016\/j.gendis.2017.04.001_bib12","doi-asserted-by":"crossref","first-page":"11334","DOI":"10.1073\/pnas.93.21.11334","article-title":"Epstein-Barr virus vectors for gene delivery to B lymphocytes","volume":"93","author":"Robertson","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/bbrc.1997.7776","article-title":"Use of EBV-based Vector\/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms","volume":"241","author":"Hirai","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/hum.1995.6.3-325","article-title":"Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer","volume":"6","author":"Ohe","year":"1995","journal-title":"Hum Gene Ther"},{"issue":"6648","key":"10.1016\/j.gendis.2017.04.001_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/38410","article-title":"Gene therapy \u2013 promises, problems and prospects","volume":"389","author":"Verma","year":"1997","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0167-7799(99)01416-X","article-title":"Gene therapy: the first decade","volume":"18","author":"Mountain","year":"2000","journal-title":"Trends Biotechnol"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/71889","article-title":"Synthetic DNA delivery systems","volume":"18","author":"Luo","year":"2000","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1016\/j.gendis.2017.04.001_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0167-7799(97)01061-5","article-title":"Integration of foreign DNA and its consequences in mammalian systems","volume":"15","author":"Doerfler","year":"1997","journal-title":"Trends Biotechnol"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng0198-56","article-title":"Repeat-induced gene silencing in mammals","volume":"18","author":"Garrick","year":"1998","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib20","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/JVI.73.2.1010-1022.1999","article-title":"Insertion of foreign DNA into an established mammalian genome can alter the methylation of cellular DNA sequences","volume":"73","author":"Remus","year":"1999","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/156652308784746440","article-title":"Episomal vectors for gene therapy","volume":"8","author":"Ehrhardt","year":"2008","journal-title":"Curr Gene Ther"},{"issue":"18","key":"10.1016\/j.gendis.2017.04.001_bib22","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.1046\/j.1432-1327.2000.01645.x","article-title":"Episomal vectors for gene expression in mammalian cells","volume":"267","author":"Van Craenenbroeck","year":"2000","journal-title":"Eur J Biochem"},{"issue":"18","key":"10.1016\/j.gendis.2017.04.001_bib23","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1093\/nar\/19.18.4861","article-title":"Efficient cDNA cloning by direct phenotypic correction of a mutant human cell line (HPRT-) using an Epstein-Barr virus-derived cDNA expression vector","volume":"19","author":"Belt","year":"1991","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib24","first-page":"143","article-title":"Extremely efficient gene transfection into lympho-hematopoietic cell lines by Epstein-Barr virus-based vectors","volume":"204","author":"Mazda","year":"1997","journal-title":"Methods"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib25","first-page":"10","article-title":"Distinct patterns of MCM protein binding in nuclei of S phase and rereplicating SV40-infected monkey kidney cells","volume":"68","author":"Friedrich","year":"2018","journal-title":"Cytom Part Soc Anal Cytol"},{"issue":"12","key":"10.1016\/j.gendis.2017.04.001_bib26","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1093\/nar\/gkg418","article-title":"The SV40 T antigen modulates CBP histone acetyltransferase activity","volume":"31","author":"Valls","year":"2003","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1016\/j.gendis.2017.04.001_bib27","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.cdd.4401273","article-title":"Reconstitution of telomerase activity combined with HPV-E7 expression allow human preadipocytes to preserve their differentiation capacity after immortalization","volume":"10","author":"Darimont","year":"2003","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib28","first-page":"2378","article-title":"BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control","volume":"70","author":"Harris","year":"1996","journal-title":"J Viol"},{"issue":"6","key":"10.1016\/j.gendis.2017.04.001_bib29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1080\/15216540701435722","article-title":"Applications of Sleeping Beauty transposons for nonviral gene therapy","volume":"59","author":"Liu","year":"2007","journal-title":"IUBMB Life"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ymthe.2005.01.010","article-title":"A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase","volume":"11","author":"Ehrhardt","year":"2005","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/138920210790886871","article-title":"DNA transposons: nature and applications in genomics","volume":"11","author":"Mu\u00f1oz-L\u00f3pez","year":"2010","journal-title":"Curr Genomics"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2174\/156652311797415827","article-title":"Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies","volume":"11","author":"Hackett","year":"2011","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.gendis.2017.04.001_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/1423-0127-20-92","article-title":"DNA transposon-based gene vehicles-scenes from an evolutionary drive","volume":"20","author":"Skipper","year":"2013","journal-title":"J Biomed Sci"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MDNA3-0042-2014","article-title":"Sleeping beauty transposition","volume":"3","author":"Ivics","year":"2015","journal-title":"Microbiol Spectr"},{"issue":"97","key":"10.1016\/j.gendis.2017.04.001_bib35","first-page":"67","article-title":"State-of-the-art human gene therapy: part I","volume":"18","author":"Wang","year":"2014","journal-title":"Gene Deliv Technol Discov Med"},{"issue":"6","key":"10.1016\/j.gendis.2017.04.001_bib36","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/mt.2010.47","article-title":"Comparative analysis of transposable element vector systems in human cells","volume":"18","author":"Grabundzija","year":"2010","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/0092-8674(93)90458-3","article-title":"Molecular mechanisms of transposition and its control","volume":"74","author":"Plasterk","year":"1993","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib38","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2174\/156652306778520647","article-title":"Transposons for gene therapy!","volume":"6","author":"Ivics","year":"2006","journal-title":"Curr Gene Ther"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.gendis.2014.12.001","article-title":"Sustained high level transgene expression in mammalian cells mediated by the optimized piggyBac transposon system","volume":"2","author":"Chen","year":"2015","journal-title":"Genes Dis"},{"issue":"20","key":"10.1016\/j.gendis.2017.04.001_bib40","doi-asserted-by":"crossref","first-page":"9239","DOI":"10.1128\/MCB.24.20.9239-9247.2004","article-title":"Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells","volume":"24","author":"Yant","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1042\/BJ20120146","article-title":"Lentiviral vectors: basic to translational","volume":"443","author":"Sakuma","year":"2012","journal-title":"Biochem J"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib42","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/mt.2012.30","article-title":"Progress in the development of hepatitis C virus vaccines","volume":"20","author":"Ertl","year":"2012","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.gendis.2017.04.001_bib43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1357-4310(97)01106-4","article-title":"The use of herpes simplex virus-based vectors for gene delivery to the nervous system","volume":"3","author":"Lachmann","year":"1997","journal-title":"Mol Med Today"},{"key":"10.1016\/j.gendis.2017.04.001_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-0556-7-1","article-title":"Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer","volume":"7","author":"Federici","year":"2009","journal-title":"Genet Vaccines Ther"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of gene therapy for X-linked severe combined immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib46","doi-asserted-by":"crossref","DOI":"10.1186\/1479-0556-2-9","article-title":"The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery","volume":"2","author":"Anson","year":"2004","journal-title":"Genet Vaccines Ther"},{"issue":"6","key":"10.1016\/j.gendis.2017.04.001_bib47","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1182\/blood-2002-02-0627","article-title":"Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells","volume":"101","author":"Laufs","year":"2002","journal-title":"Blood"},{"issue":"5644","key":"10.1016\/j.gendis.2017.04.001_bib48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.gendis.2017.04.001_bib49","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib50","first-page":"779","article-title":"Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy primary immunodeficiencies retrovirus lentivirus genome","volume":"189","author":"Fischer","year":"2005","journal-title":"Bull Acad Natl Med"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib51","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nbt0303-217","article-title":"US authorities uphold suspension of SCID gene therapy","volume":"21","author":"Fox","year":"2003","journal-title":"Nat Biotechnol"},{"issue":"9341","key":"10.1016\/j.gendis.2017.04.001_bib52","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0140-6736(02)11290-6","article-title":"Gene therapy for SCID-a complication after remarkable progress","volume":"360","author":"Buckley","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.gendis.2017.04.001_bib53","first-page":"19","article-title":"Integration target site selection for retroviruses and transposable elements","author":"Wu","year":"2004","journal-title":"Cell Mol Life"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib54","first-page":"13","article-title":"Integration site selection by retroviruses","volume":"6","author":"Cereseto","year":"2004","journal-title":"AIDS Rev"},{"key":"10.1016\/j.gendis.2017.04.001_bib55","first-page":"209","article-title":"The roles of cellular factors in retroviral integration","volume":"281","author":"Engelman","year":"2003","journal-title":"Curr Top Microbiol Immunol"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib56","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12033-007-0010-8","article-title":"Gene delivery by lentivirus vectors","volume":"36","author":"Cockrell","year":"2007","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.gendis.2017.04.001_bib57","first-page":"367","article-title":"Gene delivery by lentivirus vectors an overview","volume":"246","author":"Kafri","year":"2004","journal-title":"Methods Mol Biol"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/gt.2011.153","article-title":"Ocular gene delivery using lentiviral vectors","volume":"19","author":"Balaggan","year":"2011","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hum.2006.17.1","article-title":"Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications","volume":"17","author":"Wong","year":"2006","journal-title":"Hum Gene Ther"},{"issue":"23","key":"10.1016\/j.gendis.2017.04.001_bib60","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1523\/JNEUROSCI.22-23-10302.2002","volume":"22","author":"Azzouz","year":"2002","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib61","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/01.wco.0000084227.82329.ae","article-title":"Future and current surgical therapies in Parkinson's disease","volume":"16","author":"Betchen","year":"2003","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib62","first-page":"1","article-title":"Viral vectors: a look back and ahead on gene transfer technology","volume":"36","author":"Vannucci","year":"2013","journal-title":"New Microbiol"},{"issue":"6","key":"10.1016\/j.gendis.2017.04.001_bib63","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/hum.2011.058","article-title":"Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research","volume":"22","author":"Dropuli\u0107","year":"2011","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10565-009-9139-5","article-title":"Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells)","volume":"26","author":"Howarth","year":"2010","journal-title":"Cell Biol Toxicol"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib65","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2009.319","article-title":"Recent advances in lentiviral vector development and applications","volume":"18","author":"M\u00e1trai","year":"2010","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib66","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu Rev Virol"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib67","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1566523214666140302193709","article-title":"Basic biology of adeno-associated virus (AAV) vectors used in gene therapy","volume":"14","author":"Balakrishnan","year":"2014","journal-title":"Curr Gene Ther"},{"issue":"8","key":"10.1016\/j.gendis.2017.04.001_bib68","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrg2141","article-title":"Engineering targeted viral vectors for gene therapy","volume":"8","author":"Waehler","year":"2007","journal-title":"Nat Rev Genet"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib69","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/gt.2009.148","article-title":"Progress and prospects: immune responses to viral vectors","volume":"17","author":"Nayak","year":"2009","journal-title":"Gene Ther"},{"issue":"16","key":"10.1016\/j.gendis.2017.04.001_bib70","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib71","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00003495-200060020-00002","article-title":"Viral vectors for gene transfer: a review of their use in the treatment of human diseases","volume":"60","author":"Walther","year":"2000","journal-title":"Drugs"},{"issue":"9218","key":"10.1016\/j.gendis.2017.04.001_bib72","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0140-6736(05)73358-4","article-title":"Crisis of adenoviruses in human gene therapy","volume":"355","author":"Teramato","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib73","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jconrel.2012.04.008","article-title":"Virus-mediated gene delivery for human gene therapy","volume":"161","author":"Giacca","year":"2012","journal-title":"J Control Release"},{"issue":"11","key":"10.1016\/j.gendis.2017.04.001_bib74","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/gt.2008.55","article-title":"Adeno-associated virus integration: virus versus vector","volume":"15","author":"Smith","year":"2008","journal-title":"Gene Ther"},{"issue":"11","key":"10.1016\/j.gendis.2017.04.001_bib75","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/mt.2013.226","article-title":"Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy","volume":"21","author":"Flotte","year":"2013","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.gendis.2017.04.001_bib76","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1089\/104454902762053855","article-title":"Adenovirus and adeno-associated virus vectors","volume":"21","author":"Lai","year":"2002","journal-title":"DNA Cell Biol"},{"issue":"9","key":"10.1016\/j.gendis.2017.04.001_bib77","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/hum.1996.7.9-1145","article-title":"A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease","volume":"7","author":"Flotte","year":"1996","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib78","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/73464","article-title":"Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector","volume":"24","author":"Kay","year":"2000","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.gendis.2017.04.001_bib79","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib80","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.gendis.2017.04.001_bib81","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/mt.2014.68","article-title":"Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10","volume":"22","author":"Yang","year":"2014","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.gendis.2017.04.001_bib82","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2011.98","article-title":"Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"issue":"81","key":"10.1016\/j.gendis.2017.04.001_bib83","first-page":"111","article-title":"Recent gene therapy advancements for neurological diseases","volume":"15","author":"Nagabhushan Kalburgi","year":"2013","journal-title":"Discov Med"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib84","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.0959-9673.2004.00383.x","article-title":"J. Herpes simplex virus-based vectors","volume":"85","author":"Lachmann","year":"2004","journal-title":"Int Pathol"},{"key":"10.1016\/j.gendis.2017.04.001_bib85","first-page":"94","article-title":"Herpesvirus vectors in gene therapy","volume":"4","author":"Hukkanen","year":"2010","journal-title":"Open Virol J"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neulet.2007.11.054","article-title":"A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury","volume":"432","author":"Liu","year":"2007","journal-title":"Neurosci Lett"},{"issue":"12","key":"10.1016\/j.gendis.2017.04.001_bib87","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1089\/104454902762053864","article-title":"Gene delivery using herpes simplex virus vectors","volume":"21","author":"Burton","year":"2002","journal-title":"DNA Cell Biol"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib88","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2011.09.014","article-title":"Viral vectors for gene delivery to the central nervous system","volume":"48","author":"Lentz","year":"2011","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib89","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/v1030594","article-title":"Herpes virus amplicon vectors","volume":"1","author":"de Silva","year":"2009","journal-title":"Viruses"},{"key":"10.1016\/j.gendis.2017.04.001_bib90","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/978-1-4419-1132-2_10","article-title":"HSV as a vector in vaccine development and gene therapy","volume":"655","author":"Marconi","year":"2009","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib91","first-page":"169","article-title":"HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases","volume":"13","author":"Marconi","year":"2010","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.gendis.2017.04.001_bib92","first-page":"123","article-title":"HSV recombinant vectors for gene therapy","volume":"4","author":"Manservigi","year":"2010","journal-title":"Open Virol J"},{"key":"10.1016\/j.gendis.2017.04.001_bib93","first-page":"71","article-title":"Herpes simplex virus-based nerve targeting gene therapy in pain management","volume":"7","author":"Goss","year":"2014","journal-title":"J Pain Res"},{"key":"10.1016\/j.gendis.2017.04.001_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-340-0_1","article-title":"Oncolytic herpes simplex virus engineering and preparation","volume":"797","author":"Agarwalla","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"12 Suppl","key":"10.1016\/j.gendis.2017.04.001_bib95","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1038\/sj.gt.3302623","article-title":"Development and application of replication-incompetent HSV-1-based vectors","volume":"1","author":"Berto","year":"2005","journal-title":"Gene Ther"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib96","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1634\/stemcells.19-5-358","article-title":"Multiple applications for replication-defective herpes simplex virus vectors","volume":"19","author":"Burton","year":"2001","journal-title":"Stem Cells"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib97","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/gt.2009.19","article-title":"Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain","volume":"16","author":"Goins","year":"2009","journal-title":"Gene Ther"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib98","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/gt.2009.17","article-title":"A human trial of HSV-mediated gene transfer for the treatment of chronic pain","volume":"16","author":"Wolfe","year":"2009","journal-title":"Gene Ther"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib99","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ana.10343","article-title":"Herpes vector-mediated expression of proenkephalin reduces bone cancer pain","volume":"52","author":"Goss","year":"2002","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib100","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ymthe.2005.07.357","article-title":"Gene therapy for malignant glioma: current clinical status","volume":"12","author":"Pulkkanen","year":"2005","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.gendis.2017.04.001_bib101","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2174\/138920112800958751","article-title":"Targeted oncolytic herpes simplex viruses for aggressive cancers","volume":"13","author":"Wong","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"issue":"Pt 11","key":"10.1016\/j.gendis.2017.04.001_bib102","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1099\/vir.0.19497-0","article-title":"Genetic content and evolution of adenoviruses","volume":"84","author":"Davison","year":"2003","journal-title":"J Gen Virol"},{"issue":"8","key":"10.1016\/j.gendis.2017.04.001_bib103","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"Lasaro","year":"2009","journal-title":"Mol Ther"},{"issue":"6753","key":"10.1016\/j.gendis.2017.04.001_bib104","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/43977","article-title":"Virus treatment questioned after gene therapy death","volume":"401","author":"Lehrman","year":"1999","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.gendis.2017.04.001_bib105","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1128\/jvi.67.10.5911-5921.1993","article-title":"Packaging capacity and stability of human adenovirus type 5 vectors","volume":"67","author":"Bett","year":"1993","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.gendis.2017.04.001_bib106","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.cgt.7700539","article-title":"Intravascular adenoviral agents in cancer patients: lessons from clinical trials","volume":"9","author":"Reid","year":"2002","journal-title":"Cancer Gene Ther"},{"issue":"1-2","key":"10.1016\/j.gendis.2017.04.001_bib107","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol Genet Metab"},{"issue":"5448","key":"10.1016\/j.gendis.2017.04.001_bib108","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1126\/science.286.5448.2244","article-title":"Gene therapy death prompts review of adenovirus vector","volume":"286","author":"Marshall","year":"1999","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib109","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/cgt.2012.95","article-title":"Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers","volume":"20","author":"Choi","year":"2013","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"10.1016\/j.gendis.2017.04.001_bib110","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.gendis.2017.04.001_bib111","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.gendis.2017.04.001_bib112","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.molmed.2012.04.008","article-title":"Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond","volume":"18","author":"Kaufmann","year":"2012","journal-title":"Trends Mol Med"},{"issue":"11 Pt A","key":"10.1016\/j.gendis.2017.04.001_bib113","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1016\/j.bbamcr.2015.08.006","article-title":"Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy","volume":"1853","author":"Ramos-Kuri","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib114","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1634\/theoncologist.7-1-46","article-title":"Adenoviral gene therapy","volume":"7","author":"Vorburger","year":"2002","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.gendis.2017.04.001_bib115","doi-asserted-by":"crossref","first-page":"13565","DOI":"10.1073\/pnas.93.24.13565","article-title":"A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal","volume":"93","author":"Parks","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib116","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1073\/pnas.97.3.1002","article-title":"Optimization of the helper-dependent adenovirus system for production and potency in vivo","volume":"97","author":"Sandig","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib117","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/mthe.2001.0510","article-title":"Sustained human factor in hemophilia following systemic delivery of a gutless adenoviral vector","volume":"5","author":"Reddy","year":"2002","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib118","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1006\/mthe.2001.0323","article-title":"Development of a FLP\/frt system for generating helper-dependent adenoviral vectors","volume":"3","author":"Ng","year":"2001","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.gendis.2017.04.001_bib119","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/89343","article-title":"A gene trap vector system for identifying transcriptionally responsive genes","volume":"19","author":"Medico","year":"2001","journal-title":"Nat Biotechnol"},{"issue":"81","key":"10.1016\/j.gendis.2017.04.001_bib120","first-page":"111","article-title":"Nagabhushan Recent gene therapy advancements for neurological diseases","volume":"15","author":"Kalburgi","year":"2013","journal-title":"Discov Med"},{"key":"10.1016\/j.gendis.2017.04.001_bib121","first-page":"12.4.1","article-title":"Adenoviral vectors","author":"He","year":"2004","journal-title":"Curr Protoc Hum Genet"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib122","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","article-title":"A simplified system for generating recombinant adenoviruses","volume":"95","author":"He","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib123","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00215-0","article-title":"Approaches for generating recombinant adenovirus vectors","volume":"52","author":"Mizuguchi","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"20","key":"10.1016\/j.gendis.2017.04.001_bib124","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.gt.3301301","article-title":"Production of first generation adenovirus vectors: a review","volume":"7","author":"Danthinne","year":"2000","journal-title":"Gene Ther"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib125","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nprot.2007.135","article-title":"A protocol for rapid generation of recombinant adenoviruses using the AdEasy system","volume":"2","author":"Luo","year":"2007","journal-title":"Nat Protoc"},{"issue":"17","key":"10.1016\/j.gendis.2017.04.001_bib126","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1093\/nar\/11.17.6003","article-title":"Generation of adenovirus by transfection of plasmids","volume":"11","author":"Berkner","year":"1983","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"10.1016\/j.gendis.2017.04.001_bib127","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1089\/hum.1998.9.17-2577","article-title":"Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method","volume":"9","author":"Mizuguchi","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib128","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1128\/jvi.71.3.1842-1849.1997","article-title":"Construction of adenovirus vectors through Cre-lox recombination","volume":"71","author":"Hardy","year":"1997","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.gendis.2017.04.001_bib129","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1128\/JVI.76.9.4181-4189.2002","article-title":"Cre levels limit packaging signal excision efficiency in the Cre\/lox Adenoviral vector system","volume":"76","author":"Ng","year":"2002","journal-title":"J Virol"},{"issue":"13","key":"10.1016\/j.gendis.2017.04.001_bib130","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.1073\/pnas.91.13.6186","article-title":"Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone","volume":"91","author":"Ketner","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.gendis.2017.04.001_bib131","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1128\/jvi.70.7.4805-4810.1996","article-title":"Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli","volume":"70","author":"Chartier","year":"1996","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib132","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1073\/pnas.94.4.1414","article-title":"Recombinational construction in Escherichia coli of infectious adenoviral genomes","volume":"94","author":"Crouzet","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.gendis.2017.04.001_bib133","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/89349","article-title":"Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination","volume":"19","author":"Umana","year":"2001","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib134","doi-asserted-by":"crossref","first-page":"e92908","DOI":"10.1371\/journal.pone.0092908","article-title":"Adenovirus-mediated gene transfer in mesenchymal stem cells can be significantly enhanced by the cationic polymer polybrene","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.gendis.2017.04.001_bib135","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/gt.2014.40","article-title":"Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in HEK-293 packaging cells","volume":"21","author":"Wu","year":"2014","journal-title":"Gene Ther"},{"key":"10.1016\/j.gendis.2017.04.001_bib136","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1159\/000475909","article-title":"Engineering the rapid adenovirus production and amplification (RAPA) cell line to expedite the generation of recombinant adenoviruses","volume":"41","author":"Wei","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib137","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/ng0892-372","article-title":"Adenovirus-mediated in vivo gene transfer and expression in normal rat liver","volume":"1","author":"Jaffe","year":"1992","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib138","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0092-8674(92)90213-V","article-title":"In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium","volume":"68","author":"Rosenfeld","year":"1992","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.gendis.2017.04.001_bib139","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1073\/pnas.91.10.4407","article-title":"Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy","volume":"91","author":"Yang","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib140","first-page":"137","article-title":"Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo","volume":"3","author":"Yang","year":"1996","journal-title":"Gene Ther"},{"key":"10.1016\/j.gendis.2017.04.001_bib141","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","article-title":"Viral vectors for gene therapy: translational and clinical outlook","volume":"17","author":"Kotterman","year":"2015","journal-title":"Annu Rev Biomed Eng"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib142","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jgm.2698","article-title":"Gene therapy clinical trials worldwide to -an update","volume":"15","author":"Ginn","year":"2013","journal-title":"J Gene Med"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib143","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/1566523053544272","article-title":"Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer","volume":"5","author":"Wu","year":"2005","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.gendis.2017.04.001_bib144","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.2741\/2867","article-title":"Cancer therapy with local oncolysis and topical cytokine secretion","volume":"13","author":"Tagawa","year":"2008","journal-title":"Front Biosci Libr"},{"issue":"10","key":"10.1016\/j.gendis.2017.04.001_bib145","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.addr.2009.04.012","article-title":"Advancements in adenoviral based virotherapy for ovarian cancer","volume":"61","author":"Matthews","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib146","first-page":"3","article-title":"Adenovirus-mediated cancer gene therapy and virotherapy (Review)","volume":"25","author":"Fukazawa","year":"2010","journal-title":"Int J Mol Med"},{"issue":"8","key":"10.1016\/j.gendis.2017.04.001_bib147","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/jcb.23126","article-title":"Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development","volume":"112","author":"Aguilar","year":"2011","journal-title":"J Cell Biochem"},{"issue":"8","key":"10.1016\/j.gendis.2017.04.001_bib148","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1517\/14712598.2012.689279","article-title":"Genetic cancer vaccines: current status and perspectives","volume":"12","author":"Aurisicchio","year":"2012","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib149","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.canlet.2012.05.023","article-title":"Suicide gene therapy in cancer: where do we stand now?","volume":"324","author":"Duarte","year":"2012","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cgt.2012.87","article-title":"TAA\/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases","volume":"20","author":"Deisseroth","year":"2012","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"10.1016\/j.gendis.2017.04.001_bib151","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr Gene Ther"},{"issue":"9","key":"10.1016\/j.gendis.2017.04.001_bib152","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1089\/hum.2005.16.1016","article-title":"Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers","volume":"16","author":"Peng","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.gendis.2017.04.001_bib153","series-title":"Fields Virology","first-page":"1345","article-title":"Adenoviruses","volume":"vol. 1","author":"Wold","year":"2013"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib154","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/hed.21364","article-title":"Head and neck cancer: response to p53-based therapeutics","volume":"33","author":"Nemunaitis","year":"2011","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1517\/14712598.6.1.55","article-title":"Adenovirus p53 gene therapy","volume":"6","author":"Roth","year":"2006","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib156","first-page":"54","article-title":"A review of contusugene ladenovec (Advexin) p53 therapy","volume":"11","author":"Senzer","year":"2009","journal-title":"Curr Opin Mol Ther"},{"issue":"24","key":"10.1016\/j.gendis.2017.04.001_bib157","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1158\/1078-0432.CCR-09-1044","article-title":"Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck","volume":"15","author":"Nemunaitis","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib158","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/CAD.0b013e32832a2df9","article-title":"Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial","volume":"20","author":"Tian","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.gendis.2017.04.001_bib159","first-page":"115","article-title":"Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China","volume":"2","author":"Ma","year":"2009","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib160","first-page":"547","article-title":"An update on gene therapy in China","volume":"11","author":"Shi","year":"2009","journal-title":"Curr Opin Mol Ther"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib161","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S1016-8478(23)17606-0","article-title":"The current status of adenovirus-based cancer gene therapy","volume":"25","author":"Shirakawa","year":"2008","journal-title":"Mol Cells"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib162","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/14712598.2015.990882","article-title":"Key points of basic theories and clinical practice in rAd-p53 ( Gendicine \u2122) gene therapy for solid malignant tumors","volume":"15","author":"Li","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"10.1016\/j.gendis.2017.04.001_bib163","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/sj.cgt.7700840","article-title":"Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents","volume":"12","author":"Vaillancourt","year":"2005","journal-title":"Cancer Gene Ther"},{"issue":"5892","key":"10.1016\/j.gendis.2017.04.001_bib164","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1126\/science.1155546","article-title":"Epigenetic reprogramming by adenovirus e1a","volume":"321","author":"Ferrari","year":"2008","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib165","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.canlet.2007.02.002","article-title":"Oncolytic viruses in cancer therapy","volume":"254","author":"V\u00e4h\u00e4-Koskela","year":"2007","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib166","first-page":"798","article-title":"A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer","volume":"6","author":"Ganly","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.gendis.2017.04.001_bib167","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/sj.cgt.7700494","article-title":"Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy","volume":"9","author":"Kim","year":"2002","journal-title":"Cancer Gene Ther"},{"issue":"22","key":"10.1016\/j.gendis.2017.04.001_bib168","first-page":"1B","article-title":"Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an EkD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial","volume":"60","author":"Nemunaitis","year":"2000","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib169","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncponc0736","article-title":"Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress","volume":"4","author":"Liu","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2017.04.001_bib170","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/78638","article-title":"A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer","volume":"6","author":"Khuri","year":"2000","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib171","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/156800907780058817","article-title":"Clinical trials with oncolytic adenovirus in China","volume":"7","author":"Yu","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"issue":"31","key":"10.1016\/j.gendis.2017.04.001_bib172","doi-asserted-by":"crossref","first-page":"30675","DOI":"10.18632\/oncotarget.5169","article-title":"Progresses towards safe and efficient gene therapy vectors","volume":"6","author":"Chira","year":"2015","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.gendis.2017.04.001_bib173","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib174","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","article-title":"A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer","volume":"14","author":"Small","year":"2006","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/cgt.2008.67","article-title":"E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer","volume":"16","author":"Fukuda","year":"2008","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib176","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/0008-5472.CAN-04-3666","article-title":"Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer","volume":"65","author":"Li","year":"2005","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.gendis.2017.04.001_bib177","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1089\/104303403769211637","article-title":"Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner","volume":"14","author":"Kim","year":"2003","journal-title":"Hum Gene Ther"},{"issue":"13","key":"10.1016\/j.gendis.2017.04.001_bib178","first-page":"2559","article-title":"Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells","volume":"57","author":"Rodriguez","year":"1997","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.gendis.2017.04.001_bib179","first-page":"4663","article-title":"Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer\/promoter","volume":"62","author":"Nettelbeck","year":"2002","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib180","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/sj.cgt.7700750","article-title":"Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization","volume":"12","author":"Conrad","year":"2005","journal-title":"Cancer Gene Ther"},{"issue":"205","key":"10.1016\/j.gendis.2017.04.001_bib181","doi-asserted-by":"crossref","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","article-title":"A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci Transl Med"},{"issue":"9653","key":"10.1016\/j.gendis.2017.04.001_bib182","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.gendis.2017.04.001_bib183","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/CVI.00144-09","article-title":"Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults","volume":"16","author":"Harro","year":"2009","journal-title":"Clin Vaccine"},{"issue":"9653","key":"10.1016\/j.gendis.2017.04.001_bib184","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.gendis.2017.04.001_bib185","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1586\/14760584.2015.1083429","article-title":"Ebola virus vaccine: benefit and risks of adenovirus-based vectors","volume":"14","author":"Mennechet","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib186","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","article-title":"Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study","volume":"16","author":"De Santis","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"300","key":"10.1016\/j.gendis.2017.04.001_bib187","doi-asserted-by":"crossref","first-page":"300ra126","DOI":"10.1126\/scitranslmed.aac5745","article-title":"Chimpanzee adenovirus-and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults","volume":"7","author":"Green","year":"2015","journal-title":"Sci Transl Med"},{"issue":"15","key":"10.1016\/j.gendis.2017.04.001_bib188","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26-and modified vaccinia ankara-vectored Ebola vaccines: clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.gendis.2017.04.001_bib189","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.coi.2015.06.006","article-title":"Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine","volume":"35","author":"Zhou","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"9984","key":"10.1016\/j.gendis.2017.04.001_bib190","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib191","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4161\/hv.6.1.10116","article-title":"Prime-boost vectored malaria vaccines: progress and prospects","volume":"6","author":"Hill","year":"2010","journal-title":"Hum Vaccin"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib192","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/CVI.00552-12","article-title":"An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models","volume":"20","author":"Scallan","year":"2013","journal-title":"Clin Vaccine"},{"issue":"13","key":"10.1016\/j.gendis.2017.04.001_bib193","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.vaccine.2013.01.023","article-title":"Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-\u03b3 T cell responses in humans","volume":"31","author":"Peters","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib194","doi-asserted-by":"crossref","first-page":"e31177","DOI":"10.1371\/journal.pone.0031177","article-title":"Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin","volume":"7","author":"Alexander","year":"2012","journal-title":"Plos One"},{"issue":"12","key":"10.1016\/j.gendis.2017.04.001_bib195","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1128\/JVI.00302-12","article-title":"A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections","volume":"86","author":"Chiuppesi","year":"2012","journal-title":"J Virol"},{"issue":"5995","key":"10.1016\/j.gendis.2017.04.001_bib196","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1126\/science.1192517","article-title":"Induction of broadly neutralizing H1N1 influenza antibodies by vaccination","volume":"329","author":"Wei","year":"2010","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib197","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/COH.0b013e32833d2d2b","article-title":"Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag\/pol\/nef subtype B HIV vaccine","volume":"5","author":"Gray","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"issue":"7225","key":"10.1016\/j.gendis.2017.04.001_bib198","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature07469","article-title":"Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys","volume":"457","author":"Liu","year":"2009","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.gendis.2017.04.001_bib199","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib200","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/infdis\/jiv496","article-title":"Vaccination with 1 envelope sequences and heterologous adenovirus vectors cell responses to conserved regions: HVTN 083","volume":"213","author":"Walsh","year":"2016","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib201","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/M15-0880","article-title":"Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: trial","volume":"164","author":"Baden","year":"2016","journal-title":"Ann Intern Med"},{"issue":"17","key":"10.1016\/j.gendis.2017.04.001_bib202","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"Chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.gendis.2017.04.001_bib203","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.gendis.2017.04.001_bib204","first-page":"1","article-title":"Ebola in semen of Ebola virus disease survivors-preliminary report","author":"Deen","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.gendis.2017.04.001_bib205","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1500306","article-title":"Persistence of Ebola virus in ocular fluid during convalescence","volume":"372","author":"Varkey","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib206","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40121-015-0079-5","article-title":"Ebola virus infection: overview and update on prevention and treatment","volume":"4","author":"Mart\u00ednez","year":"2015","journal-title":"Infect Dis Ther"},{"issue":"9","key":"10.1016\/j.gendis.2017.04.001_bib207","doi-asserted-by":"crossref","first-page":"e107903","DOI":"10.1371\/journal.pone.0107903","article-title":"Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure","volume":"9","author":"Biswas","year":"2014","journal-title":"Plos One"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib208","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2009","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.gendis.2017.04.001_bib209","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib210","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/CVI.00431-07","article-title":"Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections","volume":"15","author":"Swenson","year":"2008","journal-title":"Clin Vaccine"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib211","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1128\/CVI.00467-09","article-title":"Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector","volume":"17","author":"Pratt","year":"2010","journal-title":"Clin Vaccine"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib212","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","article-title":"A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults","volume":"29","author":"Ledgerwood","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib213","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/1566523053544218","article-title":"Gene therapy for bone regeneration","volume":"5","author":"Luo","year":"2005","journal-title":"Curr Gene Ther"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib214","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/156652311795684777","article-title":"BMP-9 induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potential","volume":"11","author":"Luther","year":"2011","journal-title":"Curr Gene Ther"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib215","first-page":"1","article-title":"BMP9 signaling in stem cell differentiation and osteogenesis","volume":"2","author":"Lamplot","year":"2013","journal-title":"Am J Stem Cells"},{"key":"10.1016\/j.gendis.2017.04.001_bib216","doi-asserted-by":"crossref","first-page":"519028","DOI":"10.4061\/2010\/519028","article-title":"Mesenchymal progenitor cells and their orthopedic applications: forging a path towards clinical trials","volume":"2010","author":"Shenaq","year":"2010","journal-title":"Stem Cells Int"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib217","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4252\/wjsc.v2.i4.67","article-title":"Mesenchymal stem cells: molecular characteristics and clinical applications","volume":"2","author":"Rastegar","year":"2010","journal-title":"World J Stem Cells"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib218","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat Rev Genet"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib219","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/jor.20359","article-title":"Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells","volume":"25","author":"Luu","year":"2007","journal-title":"J Orthop Res"},{"key":"10.1016\/j.gendis.2017.04.001_bib220","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.2741\/2819","article-title":"Regulation of osteogenic differentiation during skeletal development","volume":"13","author":"Deng","year":"2008","journal-title":"Front Biosci"},{"issue":"11","key":"10.1016\/j.gendis.2017.04.001_bib221","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/jbmr.133","article-title":"Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation","volume":"25","author":"Chen","year":"2010","journal-title":"J Bone Min Res"},{"issue":"9","key":"10.1016\/j.gendis.2017.04.001_bib222","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/jcmm.12097","article-title":"Cross-talk between EGF and BMP9 signalling pathways regulates the osteogenic differentiation of mesenchymal stem cells","volume":"17","author":"Liu","year":"2013","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.gendis.2017.04.001_bib223","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biomaterials.2014.11.007","article-title":"Canonical Wnt signaling acts synergistically on BMP9-induced osteo\/odontoblastic differentiation of stem cells of dental apical papilla (SCAPs)","volume":"39","author":"Zhang","year":"2015","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.gendis.2017.04.001_bib224","doi-asserted-by":"crossref","first-page":"e11917","DOI":"10.1371\/journal.pone.0011917","article-title":"Retinoic acids potentiate BMP9-induced osteogenic differentiation of mesenchymal progenitor cells","volume":"5","author":"Zhang","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib225","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1159\/000471945","article-title":"Notch signaling augments BMP9-induced Bone formation by promoting the osteogenesis-angiogenesis coupling process in mesenchymal stem cells (MSCs)","volume":"41","author":"Liao","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib226","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000456885","article-title":"Nel-Like Molecule-1 (Nell1) is regulated by bone morphogenetic protein 9 (BMP9) and potentiates BMP9-induced osteogenic differentiation at the expense of adipogenesis in mesenchymal stem cells","volume":"41","author":"Wang","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"Suppl 1(Pt 1)","key":"10.1016\/j.gendis.2017.04.001_bib227","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2106\/00004623-200100001-00001","article-title":"Bone morphogenetic proteins: from basic science to clinical applications","volume":"83-A","author":"Reddi","year":"2001","journal-title":"J Bone Jt Surg Am"},{"issue":"8","key":"10.1016\/j.gendis.2017.04.001_bib228","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2106\/00004623-200308000-00017","article-title":"Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs)","volume":"85-A","author":"Cheng","year":"2003","journal-title":"J Bone Jt Surg Am"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib229","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/scd.2008.0130","article-title":"A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells","volume":"18","author":"Kang","year":"2009","journal-title":"Stem Cells Dev"},{"issue":"17","key":"10.1016\/j.gendis.2017.04.001_bib230","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.gt.3302298","article-title":"Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery","volume":"11","author":"Kang","year":"2004","journal-title":"Gene Ther"},{"issue":"6","key":"10.1016\/j.gendis.2017.04.001_bib231","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S8756-3282(98)00053-2","article-title":"Bone morphogenetic proteins: from basic studies to clinical approaches","volume":"22","author":"Sakou","year":"1998","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib232","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5435\/00124635-200105000-00002","article-title":"Bone regeneration: new findings and potential clinical applications","volume":"9","author":"Einhorn","year":"2001","journal-title":"J Am Acad Orthop Surg"},{"issue":"11","key":"10.1016\/j.gendis.2017.04.001_bib233","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1359\/jbmr.1999.14.11.1805","article-title":"Growth factor regulation of fracture repair","volume":"14","author":"Barnes","year":"1999","journal-title":"J Bone Min Res"},{"issue":"7","key":"10.1016\/j.gendis.2017.04.001_bib234","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2106\/00004623-199907000-00002","article-title":"The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats","volume":"81","author":"Lieberman","year":"1999","journal-title":"J Bone Jt Surg Am"},{"issue":"13","key":"10.1016\/j.gendis.2017.04.001_bib235","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.gt.3301960","article-title":"Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes","volume":"10","author":"Park","year":"2003","journal-title":"Gene Ther"},{"issue":"12","key":"10.1016\/j.gendis.2017.04.001_bib236","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2106\/00004623-200212000-00001","article-title":"Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients","volume":"84-A","author":"Govender","year":"2002","journal-title":"J Bone Jt Surg Am"},{"issue":"23","key":"10.1016\/j.gendis.2017.04.001_bib237","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1097\/00007632-200212010-00005","article-title":"Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies","volume":"27","author":"Boden","year":"2002","journal-title":"Spine (Phila Pa 1976)"},{"issue":"Suppl 1(Pt 2)","key":"10.1016\/j.gendis.2017.04.001_bib238","first-page":"S151","article-title":"Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions","volume":"83-A","author":"Friedlaender","year":"2001","journal-title":"J Bone Jt Surg Am"},{"issue":"23","key":"10.1016\/j.gendis.2017.04.001_bib239","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1097\/00007632-200212010-00004","article-title":"Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies","volume":"27","author":"Johnsson","year":"2002","journal-title":"Spine (Phila Pa 1976)"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib240","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/107632703764664819","article-title":"Human mesenchymal stem cells transduced with recombinant bone morphogenetic protein-9 adenovirus promote osteogenesis in rodents","volume":"9","author":"Dayoub","year":"2003","journal-title":"Tissue Eng"},{"issue":"6","key":"10.1016\/j.gendis.2017.04.001_bib241","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/104303401300057423","article-title":"Morphologic analysis of BMP-9 gene therapy-induced osteogenesis","volume":"12","author":"Varady","year":"2001","journal-title":"Hum Gene Ther"},{"issue":"8","key":"10.1016\/j.gendis.2017.04.001_bib242","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.BRS.0000058946.64222.92","article-title":"Potential use of Sox9 gene therapy for intervertebral degenerative disc disease","volume":"28","author":"Paul","year":"2003","journal-title":"Spine (Phila Pa 1976)"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib243","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jhsa.2004.08.010","article-title":"Characterization of adenovirus-mediated gene transfer in rabbit flexor tendons","volume":"30","author":"Mehta","year":"2005","journal-title":"J Hand Surg Am"},{"issue":"6","key":"10.1016\/j.gendis.2017.04.001_bib244","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2106\/00004623-200706000-00021","article-title":"BMP-14 gene therapy increases tendon tensile strength in a rat model of Achilles tendon injury","volume":"89","author":"Bolt","year":"2007","journal-title":"J Bone Jt Surg Am"},{"issue":"1","key":"10.1016\/j.gendis.2017.04.001_bib245","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1128\/JVI.80.1.27-37.2006","article-title":"Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses","volume":"80","author":"Xiong","year":"2006","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib246","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.mt.6300375","article-title":"Immunization against the transgene but not the TetReduces expression from gutless adenoviral vectors in the brain","volume":"16","author":"Xiong","year":"2008","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib247","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/jgm.867","article-title":"A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter","volume":"8","author":"Shi","year":"2006","journal-title":"J Gene Med"},{"issue":"11","key":"10.1016\/j.gendis.2017.04.001_bib248","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/gt.2011.58","article-title":"Self-inactivating helper virus for the production of high-capacity adenoviral vectors","volume":"18","author":"Gonzalez-Aparicio","year":"2011","journal-title":"Gene Ther"},{"issue":"3","key":"10.1016\/j.gendis.2017.04.001_bib249","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ymthe.2006.05.006","article-title":"Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells","volume":"14","author":"Candolfi","year":"2006","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.gendis.2017.04.001_bib250","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.gendis.2017.04.001_bib251","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.molcel.2015.02.032","article-title":"Expanding the biologist's toolkit with CRISPR-Cas9","volume":"58","author":"Sternberg","year":"2015","journal-title":"Mol Cell"},{"issue":"5","key":"10.1016\/j.gendis.2017.04.001_bib252","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.gendis.2017.04.001_bib253","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/08830185.2015.1018419","article-title":"Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy","volume":"34","author":"Figueroa","year":"2015","journal-title":"Int Rev Immunol"}],"container-title":["Genes &amp; Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304217300272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304217300272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:23:29Z","timestamp":1762449809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304217300272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":253,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S2352304217300272"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2017.04.001","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2017.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017, Chongqing Medical University. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}